scott@vtx-cpd.com
Forum Replies Created
-
AuthorPosts
-
Replying to Angela Tiivel 10/08/2025 - 09:53
Hi Angela,
Thanks for your message. I understand how frustrating it can be to lose access to products like Denamarin, Zentonil, and Samylin, as they are widely used in many countries for hepatic support. In situations where these aren’t available, the goal is to select from what you do have access to, ensuring you can still provide adequate doses of the key active ingredients with the strongest evidence for liver protection, namely S-adenosylmethionine (SAMe) and silybin (the bioactive extract of milk thistle), ideally in combination with antioxidants such as vitamin E.
Of the products you mentioned, VETEXPERT Hepatiale Forte Advanced would probably be my first choice for most cases, as it contains SAMe together with phosphatidylcholine, which aids hepatocyte membrane stability and can improve bioavailability of silybin if given together in some cases. However, if the formulation you have does not already include silybin, I would look at adding this separately, either through a combination product or a stand-alone silybin supplement with proven bioavailability (often in the form of silybin–phosphatidylcholine complexes).
DRN Epato and Bioiberica Prolivet are also reasonable options — both can provide useful support depending on their exact composition in your market. Epato products often contain silybin, phosphatidylcholine, and sometimes artichoke extract or other antioxidants; Prolivet typically contains silybin and other liver-supportive nutrients. The main thing is to check the label for the actual amount of silybin and/or SAMe per tablet or capsule, as the doses in many nutraceuticals are quite low compared to those used in published studies.
When selecting and dosing:
SAMe: Aim for a therapeutic dose of roughly 18–20 mg/kg once daily on an empty stomach. This helps maximise absorption and avoids degradation by food.
Silybin: Aim for 4–5 mg/kg once daily (or divided twice daily), ideally in a phosphatidylcholine-bound form for improved absorption.
Vitamin E: May be beneficial in chronic hepatopathies or where oxidative stress is suspected, but dosing should be tailored to avoid excess.
If a single product doesn’t contain both SAMe and silybin in adequate amounts, you can combine two complementary products to reach the desired doses. For example, you might use Hepatiale Forte Advanced to supply adequate SAMe and then pair it with Epato to provide the silybin component.
Regarding your comment on liver enzyme improvements after discontinuing Apoquel, there have been occasional reports of mild ALT or ALP elevations in dogs on oclacitinib, though it’s not considered a common side effect. In cases where there’s a temporal association between starting Apoquel and enzyme elevation, particularly if other causes are not identified, a trial off the medication can help clarify the relationship. If Apoquel is needed for pruritus control but liver enzyme elevations persist or worsen, switching to an alternative antipruritic may be considered.
I really hope you are enjoying the course.
Best regards,
Scott
Replying to Victoria R. 08/08/2025 - 14:26
Hi Tori — that’s really interesting, especially your comment about relatively few patients developing GI signs. Do you find there’s a particular breed or signalment where GI side effects are more common with ciclosporin?
Scott 🙂
Replying to Victoria R. 08/08/2025 - 14:31
No problem!
I am looking forward to trying it too!
Scott 🙂
Great post, Tori — totally agree that those “bingo” moments can change everything! Do you find written questionnaires help at all, or do you prefer to gather history verbally during consults?
I have always wondered about sending out pre consultation questions for clients to complete but have never done it.
Scott 🙂
Replying to Sarah Keir 02/08/2025 - 18:25
Hahahaha!
There has to be a home for our old university gowns!
Scott 🙂
Replying to valerie dromey 03/08/2025 - 20:57
Thanks Valerie.
Really lovely to hear from you. I hope you are well.
I agree the mild PT increase isn’t the most urgent concern here, especially with a non-haemorrhagic effusion, though the pallor is still something to keep in mind. Your points on possible metastatic disease and the impression of an enlarged cardiac silhouette are well taken, although the radiology report describes the cardiac silhouette, pleural space, and mediastinum as normal.
Radiographs show multiple, well-defined, smoothly marginated soft tissue nodules scattered throughout the right middle lung lobe, the largest measuring about 1.4 cm. These were seen on all projections. The radiologist’s interpretation was that these likely represent metastatic neoplasia, less likely granulomas. The included cranial abdominal serosal detail is markedly reduced, consistent with the peritoneal effusion.
Given these findings, I think the thoracic films do support metastatic disease, which obviously pushes the prognosis toward guarded to poor. If there hadn’t been clear evidence of metastatic spread, I might have been inclined to pursue more advanced imaging such as abdominal/thoracic CT with angiography to map out the adrenal mass in relation to the caudal vena cava and surrounding structures, and also to perform adrenal functional testing (e.g., plasma or urine metanephrines) to rule in or out a pheochromocytoma.
We did analyse the peritoneal fluid—clear modified transudate (TP ~32 g/L, PCV <1%) with bland cytology—consistent with either right-sided heart failure or increased hydrostatic pressure from caval or portal hypertension.
I share your thoughts on diuretics. If echo suggested significant cardiac involvement, I’d consider a cautious trial, but if the ascites is primarily from caval obstruction, serial abdominocenteses might provide better relief without compromising perfusion in this already hypotensive patient.
Thank you again for your brilliant comments!
Scott 🙂
Replying to Riley D. 03/08/2025 - 21:02
Hey Riley,
Thanks for sharing the case. I’ll be curious to see how things go with his check up and whether you detect any effusion you can tap for RT-qPCR.
For what it’s worth, I’ve just been following an older kitty, “Emma Jane,” with a long, twisty file: chronic pleural effusion, persistent hyper-globulinaemia, a static right-ventricular mass, previous pericardiectomy, and a relapse of presumptive FIP now on a second 84-day GS course. Her echo shows mild HCM-type changes plus that ventricular mass, and her troponin’s been intermittently high—so I’m watching her as another possible example of the cardiac-FIP spectrum. The one thing that does not make sense with her is her age!
Keep us posted.
Cheers,
Scott
Replying to Victoria R. 01/08/2025 - 08:27
Welcome Tori!
We are so lucky to have you join us.
Thank you for developing such a brilliant course!
Scott 🙂
Replying to Steph Sorrell 29/07/2025 - 09:01
Thanks Steph!
Great to hear from you. Hope all is well.
Scott 🙂
Felipe!
Thank you again for sharing another brilliant video!
Scott 🙂
Replying to Christina Frigast 01/08/2025 - 12:50
Thank you so much got sharing.
Really interesting. I am glad you got things checked out. So much trickier with our own pets indeed.
Keep us posted.
Scott 🙂
Replying to Liz Bode 30/07/2025 - 19:57
So helpful Liz.
Thanks for sharing.
Scott 🙂
Replying to Jo T. 30/07/2025 - 22:05
That is very cool!
Will be exciting to build a service!
Scott 🙂
Thank you so much for the questions Mark.
I hope you are enjoying the course.
Thank you so much for your participation.
Scott:)
Hi Christina,
Thanks for sending this through. I’d agree with Jo that the photo looks most consistent with a cataract, and PRA would be much less likely in such a young dog, particularly with normal retinal appearance. If unilateral, trauma or developmental causes are more likely, though early changes in the other eye are possible.
Interesting case!
Scott 🙂
-
AuthorPosts